{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:51:55Z","timestamp":1792623115538,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jtha.2025.09.040","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:35:22Z","timestamp":1761550522000},"page":"520-529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Considerations of safety for women prescribed apixaban or rivaroxaban who breastfeed\u2014a physiologically based pharmacokinetic analysis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4362-940X","authenticated-orcid":false,"given":"Andrew S.","family":"Butler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4197-8294","authenticated-orcid":false,"given":"Susan","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5630-7990","authenticated-orcid":false,"given":"Roopen","family":"Arya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4582-6231","authenticated-orcid":false,"given":"Jignesh P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.09.040_bib1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.7326\/0003-4819-143-10-200511150-00006","article-title":"Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study","volume":"143","author":"Heit","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2025.09.040_bib2","year":"2024"},{"key":"10.1016\/j.jtha.2025.09.040_bib3","doi-asserted-by":"crossref","first-page":"440.e1","DOI":"10.1016\/j.ajog.2023.12.038","article-title":"Maternal mortality in the United States: are the high and rising rates due to changes in obstetrical factors, maternal medical conditions, or maternal mortality surveillance?","volume":"230","author":"Joseph","year":"2024","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jtha.2025.09.040_bib4","series-title":"Reducing the risk of venous thromboembolism during pregnancy and the puerperium green-top guideline No. 37a","year":"2015"},{"key":"10.1016\/j.jtha.2025.09.040_bib5","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1111\/jth.12020","article-title":"Women\u2019s views on and adherence to enoxaparin during pregnancy and the puerperium","volume":"10","author":"Patel","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.040_bib6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.thromres.2018.11.020","article-title":"Women\u2019s views, adherence and experience with postnatal thromboprophylaxis","volume":"173","author":"Guimicheva","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.09.040_bib7","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s11239-019-01952-4","article-title":"Factors associated with women\u2019s adherence to postpartum thromboprophylaxis","volume":"49","author":"Rottenstreich","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2025.09.040_bib8","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1016\/j.jtha.2024.06.019","article-title":"Preferences of pregnant women for postpartum thromboprophylaxis: the bicentric PREFER-PostPartum study","volume":"22","author":"Blondon","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.040_bib9","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/1471-0528.18251","article-title":"Considering medication compliance when offering thromboprophylaxis in the postnatal period","volume":"132","author":"Gibbs","year":"2025","journal-title":"BJOG"},{"key":"10.1016\/j.jtha.2025.09.040_bib10","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s11096-018-0734-5","article-title":"Factors influencing the recruitment of lactating women in a clinical trial involving direct oral anticoagulants: a qualitative study","volume":"40","author":"Zhao","year":"2018","journal-title":"Int J Clinical Pharm"},{"key":"10.1016\/j.jtha.2025.09.040_bib11","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.chest.2016.01.021","article-title":"The direct factor Xa inhibitor rivaroxaban passes into human breast milk","volume":"150","author":"Wiesen","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.09.040_bib12","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1089\/bfm.2019.0230","article-title":"Rivaroxaban concentration in breast milk during breastfeeding: a case study","volume":"14","author":"Saito","year":"2019","journal-title":"Breastfeed Med"},{"key":"10.1016\/j.jtha.2025.09.040_bib13","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1182\/blood.2020006231","article-title":"Are apixaban and rivaroxaban distributed into human breast milk to clinically relevant concentrations?","volume":"136","author":"Zhao","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.09.040_bib14","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1002\/ajh.25652","article-title":"Investigation of dabigatran secretion into breast milk: implications for oral thromboprophylaxis in post-partum women","volume":"95","author":"Ayuk","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2025.09.040_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1089\/bfm.2019.0124","article-title":"Rivaroxaban treatment in two breastfeeding mothers: a case series","volume":"15","author":"Muysson","year":"2020","journal-title":"Breastfeed Med"},{"key":"10.1016\/j.jtha.2025.09.040_bib16","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1097\/AOG.0000000000004388","article-title":"Transfer of apixaban into human milk","volume":"137","author":"Datta","year":"2021","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jtha.2025.09.040_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.thromres.2024.04.003","article-title":"Potential treatment option of rivaroxaban for breastfeeding women: a case series","volume":"237","author":"Yamashita","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.09.040_bib18","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMp1817420","article-title":"\u201cIs it safe?\u201d\u2014the many unanswered questions about medications and breastfeeding","volume":"380","author":"Byrne","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.09.040_bib19","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/cpt.2325","article-title":"Improving knowledge on safety is key to enabling drug access for pregnant and breastfeeding women","volume":"110","author":"Chappell","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtha.2025.09.040_bib20","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/cpt.2212","article-title":"Assuring access to safe medicines in pregnancy and breastfeeding","volume":"110","author":"Nooney","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtha.2025.09.040_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.733823","article-title":"Maternal-fetal pharmacology of drugs: a review of current status of the application of physiologically based pharmacokinetic models","volume":"9","author":"Chaphekar","year":"2021","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jtha.2025.09.040_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.840710","article-title":"Application of a physiologically based pharmacokinetic approach to predict theophylline pharmacokinetics using virtual non-pregnant, pregnant, fetal, breast-feeding, and neonatal populations","volume":"10","author":"Abduljalil","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jtha.2025.09.040_bib24","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/cpt.2530","article-title":"Development of a generic physiologically-based pharmacokinetic model for lactation and prediction of maternal and infant exposure to ondansetron via breast milk","volume":"111","author":"Job","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtha.2025.09.040_bib25","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/psp4.13090","article-title":"Supplementing clinical lactation studies with PBPK modeling to inform drug therapy in lactating mothers: prediction of primaquine exposure as a case example","volume":"13","author":"Pan","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtha.2025.09.040_bib26","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/psp4.12562","article-title":"Physiologically-based pharmacokinetic modeling for the prediction of a drug-drug interaction of combined effects on P-glycoprotein and cytochrome P450 3A","volume":"9","author":"Otsuka","year":"2020","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jtha.2025.09.040_bib27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10928-023-09867-7","article-title":"Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates","volume":"50","author":"Otsuka","year":"2023","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.jtha.2025.09.040_bib28","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/psp4.13202","article-title":"A guide to developing population files for physiologically-based pharmacokinetic modeling in the Simcyp Simulator","volume":"13","author":"Curry","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jtha.2025.09.040_bib29","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/psp4.13232","article-title":"A tutorial on physiologically based pharmacokinetic approaches in lactation research","volume":"13","author":"Pansari","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jtha.2025.09.040_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1517069","article-title":"Postpartum changes in maternal physiology and milk composition: a comprehensive database for developing lactation physiologically-based pharmacokinetic models","volume":"16","author":"Deferm","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jtha.2025.09.040_bib31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1460-9592.2010.03323.x","article-title":"Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice","volume":"21","author":"Johnson","year":"2011","journal-title":"Pediatr Anesth"},{"key":"10.1016\/j.jtha.2025.09.040_bib32","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/psp4.12798","article-title":"Development and application of a pediatric mechanistic kidney model","volume":"11","author":"Salem","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jtha.2025.09.040_bib33","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2165\/00003088-200645090-00005","article-title":"Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children","volume":"45","author":"Johnson","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2025.09.040_bib34","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/lt.20519","article-title":"Changes in liver volume from birth to adulthood: a meta-analysis","volume":"11","author":"Johnson","year":"2005","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jtha.2025.09.040_bib35","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40262-013-0089-y","article-title":"Differences in cytochrome p450-mediated pharmacokinetics between Chinese and Caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling","volume":"52","author":"Barter","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2025.09.040_bib36","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/psp4.13251","article-title":"Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women","volume":"13","author":"Ning","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jtha.2025.09.040_bib37","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/psp4.12707","article-title":"Development of physiologically-based pharmacokinetic models for standard of care and newer tuberculosis drugs","volume":"10","author":"Humphries","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jtha.2025.09.040_bib38","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10928-020-09711-2","article-title":"Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy","volume":"47","author":"Abduljalil","year":"2020","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.jtha.2025.09.040_bib39","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ajog.2004.08.030","article-title":"Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy","volume":"192","author":"Tracy","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jtha.2025.09.040_bib40","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/clpt.2008.1","article-title":"Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study","volume":"84","author":"Hebert","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jtha.2025.09.040_bib41","unstructured":"Food and Drugs Administration. Center for Drug Evaluation and Research Application Number: 202439Orig1s035. Pharmacology Review(s)\u2014Rivaroxaban."},{"key":"10.1016\/j.jtha.2025.09.040_bib42","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40262-013-0090-5","article-title":"Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban","volume":"53","author":"Willmann","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2025.09.040_bib43","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12959-018-0188-y","article-title":"Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study","volume":"16","author":"Lensing","year":"2018","journal-title":"Thromb J"},{"key":"10.1016\/j.jtha.2025.09.040_bib44","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S2352-3026(19)30219-4","article-title":"Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial","volume":"7","author":"Male","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2025.09.040_bib45","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/jth.14813","article-title":"Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr Phase 3 dose-exposure-response evaluation","volume":"18","author":"Young","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.09.040_bib47","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/0002-9343(89)90021-1","article-title":"Pharmacokinetics of three newer quinolones in pregnant and lactating women","volume":"87","author":"Giamarellou","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.jtha.2025.09.040_bib48","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1592\/phco.21.7.669.34574","article-title":"Active transport of nitrofurantoin into human milk","volume":"21","author":"Gerk","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jtha.2025.09.040_bib49","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/psp4.13243","article-title":"A close examination of BCRP\u2019s role in lactation and methods for predicting drug distribution into milk","volume":"13","author":"Sychterz","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jtha.2025.09.040_bib50","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/0002-9378(72)90824-1","article-title":"Secretion of methotrexate into human milk","volume":"112","author":"Johns","year":"1972","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jtha.2025.09.040_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1507551","article-title":"Evaluation of mathematical models for predicting medicine distribution into breastmilk\u2014considering biological heterogeneity","volume":"15","author":"Heo","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jtha.2025.09.040_bib52","doi-asserted-by":"crossref","DOI":"10.1111\/mcn.12938","article-title":"Quantifying breast milk intake by term and preterm infants for input into paediatric physiologically based pharmacokinetic models","volume":"16","author":"Yeung","year":"2020","journal-title":"Maternal & Child Nutrition"},{"key":"10.1016\/j.jtha.2025.09.040_bib53","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.3390\/nu16234205","article-title":"The deuterium oxide dilution method to quantify human milk intake volume of infants: a systematic review\u2014a contribution from the ConcePTION project","volume":"16","author":"Cloostermans","year":"2024","journal-title":"Nutrients"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362500666X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362500666X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:19:35Z","timestamp":1778224775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362500666X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S153878362500666X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.09.040","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Considerations of safety for women prescribed apixaban or rivaroxaban who breastfeed\u2014a physiologically based pharmacokinetic analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.09.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}